Skip to Main content Skip to Navigation
Journal articles

Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat hepatitis C recurrence after liver transplantation only in genotype 1. Results from the CO23 ANRS CUPILT study.

Pauline Houssel-Debry 1 Audrey Coilly 2, 3, 4 Claire Fougerou-Leurent 1, 5 Caroline Jezequel 6, 1 Christophe Duvoux 7 Victor Ledinghen 8 Sylvie Radenne 9 Nassim Kamar 10, 11 Vincent Leroy 12 Vincent Di Martino 13 Louis d'Alteroche 14, 15 Valerie Canva-Delcambre Filomena Conti 16, 17, 18 Jérôme Dumortier 19 Helene Montialoux Pascal Lebray 20, 21 Danielle Botta-Fridlund 22 Rodolphe Anty 23, 24 Christophe Moreno 25 Christine Silvain 26 Camille Besch Philippe Perré Claire Francoz 27 Armand Abergel 28 François Habersetzer 29 Maryline Debette-Gratien 30 Alexandra Rohel Alpha Diallo Emilie Rossignol 5, 1 Helene Danjou 5, 1 Aurelie Veislinger 1 Jean-Charles Duclos-Vallée 4, 31, 3, 32 Georges-Philippe Pageaux 33
Abstract : Meeting Abstract: 925
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01412958
Contributor : Laurent Jonchère <>
Submitted on : Friday, December 9, 2016 - 10:26:30 AM
Last modification on : Monday, October 12, 2020 - 10:28:17 AM

Identifiers

  • HAL Id : hal-01412958, version 1

Citation

Pauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, Caroline Jezequel, Christophe Duvoux, et al.. Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat hepatitis C recurrence after liver transplantation only in genotype 1. Results from the CO23 ANRS CUPILT study.. Hepatology, Wiley-Blackwell, 2017, 63 (1 SUPP), pp.465A--465A. ⟨hal-01412958⟩

Share

Metrics

Record views

610